| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
L-AP4 monohydrate manufacturers
|
| | L-AP4 monohydrate Basic information |
| Product Name: | L-AP4 monohydrate | | Synonyms: | L-AP4 monohydrate;L AP4 monohydrate,L-AP-4 monohydrate,LAP4 monohydrate;Butanoic acid, 2-amino-4-phosphono-, hydrate (1:1), (2S)- | | CAS: | 2247534-79-6 | | MF: | | | MW: | 201.12 | | EINECS: | | | Product Categories: | | | Mol File: | 2247534-79-6.mol |  |
| | L-AP4 monohydrate Chemical Properties |
| storage temp. | 4°C, away from moisture and light | | form | Solid | | color | White to off-white |
| | L-AP4 monohydrate Usage And Synthesis |
| Uses | L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively[1][2]. | | Biological Activity | L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively[1][2].
L-AP4 (5-30 μg, intrathecal inhection 4-5 days) significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. Intrathecal administration of different doses of L-AP4 is not associated with any evident motor dysfunction[2].Intrathecal injection of 30 μg of L-AP4 does not significantly alter the paw withdrawal latency in these normal rats[2].Topical application of 5 to 50 μM L-AP4 to the spinal cord significantly inhibited the evoked response of neurons to touch, pressure, pinch, and von Frey filaments in a concentration-dependent fashion[2]. Animal Model: Rats.[2] | | in vivo | L-AP4 (5-30 μg, intrathecal inhection 4-5 days) significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. Intrathecal administration of different doses of L-AP4 is not associated with any evident motor dysfunction[2].
Intrathecal injection of 30 μg of L-AP4 does not significantly alter the paw withdrawal latency in these normal rats[2].
Topical application of 5 to 50 μM L-AP4 to the spinal cord significantly inhibited the evoked response of neurons to touch, pressure, pinch, and von Frey filaments in a concentration-dependent fashion[2].
| Animal Model: | Rats.[2]
| | Dosage: | 5-30 μg. | | Administration: | Intrathecal inhection 4-5 days. | | Result: | Dose-dependently increased paw withdrawal threshold. |
| | IC 50 | mGlu4: 0.13 μM (EC50); mGlu8: 0.29 μM (EC50); mGlu6: 1.0 μM (EC50); mGlu7: 249 μM (EC50) | | References | [1]. Selvam C, et al. Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites. J Med Chem. 2018 Mar 8;61(5):1969-1989.
[2]. Chen SR, et al. Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured Rats. J Pharmacol Exp Ther. 2005 Jan;312(1):120-6. |
| | L-AP4 monohydrate Preparation Products And Raw materials |
|